Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #688

    Uden nogen egentlig betydning, da det var tidligere gevinst, der smuttede.

    1 Reply Last reply
    0
    • A Offline
      A Offline
      AaBforever
      wrote on sidst redigeret af
      #689

      Det var et bump på vejen..også for mig. For ikke at tale om da bavianen fejlede med Prostvac.

      1 Reply Last reply
      0
      • A Offline
        A Offline
        AaBforever
        wrote on sidst redigeret af
        #690

        Den sved...

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #691

          av ja, der var jeg heldigvis ikke inde. Men der var en skribent her i tjatten, der sagde at han tabte en mio.

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #692

            Jo men det er jo blevet opvejet at historien om at citi siger at det hele er indregnet, hvis kursen ligger under 2300.

            1 Reply Last reply
            0
            • A Offline
              A Offline
              AaBforever
              wrote on sidst redigeret af
              #693

              Jeg tror på at Genmab er i en uptrend fremadrettet ud fra hvad alle med indsigt i casen her på sitet skriver.

              1 Reply Last reply
              0
              • N Offline
                N Offline
                Noma9
                wrote on sidst redigeret af
                #694

                @thenote du har ramt rimelig godt med analyse af chemm, så hvad mener du om Genmab kurs den næste måneds tid rent teknisk?

                1 Reply Last reply
                0
                • A Offline
                  A Offline
                  AaBforever
                  wrote on sidst redigeret af
                  #695

                  Netop Bulder ..Peter Verdult er ikke hvem som helst. Om vi kan lide det eller ej..US styrer kursen.

                  1 Reply Last reply
                  0
                  • A Offline
                    A Offline
                    AaBforever
                    wrote on sidst redigeret af
                    #696

                    Nå..der er en ny spændende dag i morgen. Good luck to all:-)

                    1 Reply Last reply
                    0
                    • N Offline
                      N Offline
                      Noma9
                      wrote on sidst redigeret af
                      #697

                      Mange tak skal du have for din indsigt.

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #698

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #699

                          Teknisk: US Health care i gennembrud på vejmod nye højder https://www.proinvestor.com/investornyt/674096/teknisk-us-health-care-i-gennembrud-pa-vejmod-nye-hojder

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #700

                            Fredagens danske avisuddrag med
                            Chr.Hansen, Mærsk og Nemlig: https://www.proinvestor.com/investornyt/674089/fredagens-danske-avisuddrag-med-chrhansen-maersk-og-nemlig

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #701

                              Just a moment...

                              favicon

                              (www.firstwordpharma.com)

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #702

                                TG Therapeutics vil gennemgå deres MS data

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #703

                                  Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS https://www.novartis.com/news/media-releases/kesimpta-ofatumumab-data-aan-showed-reduction-disability-progression-independent-relapse-activity-newly-diagnosed-patients-rms

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #704

                                    Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
                                    The MANHATTAN Nonrandomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/article-abstract/2778195

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #705

                                      not a fan of Zacks, but anyway; The Zacks Consensus Estimate for Imbruvica, Darzalex and Stelara is pegged at $1.2 billion, $1.22 billion and $2.18 billion, respectively. https://www.nasdaq.com/articles/will-jj-jnj-kickstart-pharma-q1-earnings-with-a-beat-2021-04-15

                                      1 Reply Last reply
                                      0
                                      • R Offline
                                        R Offline
                                        Rondo
                                        wrote on sidst redigeret af
                                        #706

                                        jamen vi banker da på 2180..... spændende hvornår vi kommer igennem.... 🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #707

                                          The Lancet - Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00056-5/fulltext

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger